Available online at www.sciencedirect.com
SCIENCE DIRECT®
Bioorganic & Medicinal Chemistry Letters 16 (2006) 1506–1509
Bioorganic & Medicinal Chemistry Letters

Synthesis and biological investigation of new 4″-malonyl tethered derivatives of erythromycin and clarithromycin

Daniel Sherman,[a] Liqun Xiong,[b] Alexander S. Mankin[b] and Artem Melman[a,*]

[a]*Department of Organic Chemistry, Hebrew University of Jerusalem, Jerusalem 91904, Israel*
[b]*Center for Pharmaceutical Biotechnology, University of Illinois, Chicago, IL 60607, USA*

Received 25 August 2005; accepted 12 December 2005
Available online 4 January 2006

Abstract—A new approach to 4″-substituted derivatives of erythromycin and clarithromycin was developed by converting them into corresponding 4″-malonic monoesters. Subsequent carbodiimide coupling with alcohols and amines provided new macrolide derivatives that are capable of binding to 50S ribosomal subunits and inhibiting protein synthesis in cell-free system.

Erythromycin **1a** and other macrolide antibiotics (Scheme 1) have been used for the treatment of a variety of bacterial infections for the past 50 years. Low toxicity and cost as well as low incidence of side effects resulted in extensive use of erythromycin both for treatment of infections and prophylactic purposes.[1] The active use of the drug resulted in a wide spread of macrolide resistance in a number of pathogenic strains. As an example, in Asia the majority (up to 80% in Hong Kong) of *Streptococcus pneumoniae* strains carry resistance to macrolide antibiotics.[2] Attempts to improve relatively poor bioavailability of erythromycin, increase its spectrum of activity, and overcome bacterial resistance resulted in synthesis and investigation of a number of semisynthetic macrolide derivatives such as clarithromycin **1b**, azithromycin **1c**, and roxithromycin **1d**. The most recent generation of macrolide antibiotics, such as telithromycin (KETEK®) **1e** and ABT-773 **1f**,[3] possesses enhanced biological activity; however, their synthesis is much more complicated.

All macrolide antibiotics share a similar mechanism of action which involves selective binding to the 50S subunit of bacterial ribosome resulting in inhibition of protein synthesis. Genetic, biochemical, and more recent crystallographic studies of ribosome–macrolide complexes have indicated that macrolides bind in nascent peptide exit tunnel thus blocking polypeptide chain growth.[4a–i] X-ray structures showed that desosamine sugar at position 5 of the macrolide lactone ring provides very important contribution to the overall binding energy of the drug.[4a,i,5] Indeed, acylation of 2′-hydroxy group of desosamine drastically decreases antibacterial activity.[6] Newer macrolide derivatives such as telithromycin, ABT-733 or bridged ketolides possess additional heterocyclic arm which is most likely responsible for their enhanced antibacterial activity.[3]

The extent of involvement of the cladinose sugar in ribosome binding is less clear. While a simple removal of the cladinose moiety was found to substantially decrease the activity of erythromycin,[7] a number of highly active macrolide derivatives, such as acylides[8] and ketolides,[9]



1a R=H, R^1=R^2=OH, R^3=H, R^4= cladinose, X= C=O
1b R=Me, R^1=R^2=OH, R^3=H, R^4= cladinose, X= C=O
1c R=H, R^1=R^2=OH, R^3=H, R^4= cladinose, X= N(Me)CH_2
1d R=H, R^1=R^2=OH, R^3=H, R^4= cladinose, X= C=N$OCH_2OCH_2CH_2OMe$
1e R=Me, R^1,R^2= -OC(O)N(CH_2)$_3$–N(=N)–3-Pyridyl, R^3, R^4=O, X= C=O
1f R=CH_2CH=CH-3-Quinolinyl, R^1,R^2= -OC(O)NH- , R^3, R^4=O, X= C=O

Scheme 1. Erythromycin and semisynthetic macrolide antibiotics.

Keywords: Macrolides; Ribosome; Antibiotics; Tethering.
* Corresponding author. Tel.: +97226585279; fax: +97226585345; e-mail: amelman@chem.ch.huji.ac.il

0960-894X/$ - see front matter © 2005 Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmcl.2005.12.033

do not contain cladinose. There were relatively few attempts to modify cladinose residues to increase the bioavailability or activity of erythromycin. Attempts to introduce simple alkanoyl[6,10] and polyunsaturated alkenoyl[11] substituents into 4″ position of erythromycin involved either diacylation at 2′ and 4″ positions followed by a selective hydrolysis, or selective formylation of 2′-position followed by the acylation of 4″-position and selective hydrolysis of 2′ formyl group.[6] Resultant compounds exhibited lower[10] or substantially lower[12] than erythromycin antibacterial activity,[13] most probably due to decreased bioavailability. High nucleotide content of ribosome gives rise to a number of possible interactions such as hydrogen bonding, π-stacking as well as electrostatic interactions. Erythromycin and clarithromycin derivatives carrying cladinose sugar modified with functional groups capable of such types of interaction have a potential to exhibit increased affinity toward ribosomes including mutant ribosomes of resistant bacteria. Indeed, Fernandes and co-authors demonstrated substantial enhancing of antibacterial activity through alteration of 4″-position of erythromycin oxime derivatives with heteroatom-functionalized side chains.[14] This type of derivatization, however, is relatively difficult and laborious to perform by previously described methods.[6]

We recently reported on a new one-pot method for tethering of organic molecules through the formation of non-symmetric malonate derivatives.[15] This method enables efficient binding of alcohols and amines under very mild conditions in the absence of acylation catalysts. Since malonate linker is biocompatible and reasonably stable, we were attracted by the possibility to derivatize cladinose sugar of macrolide antibiotics by introducing functional groups that could influence binding of the drug to the ribosome. In contrast to all previous attempts for selective 4″-derivatization of macrolides, our synthetic approach to 4″-tethered macrolide derivatives of type **5** (Scheme 2) involved the use of one common intermediate of type **4**.

In line with this approach, 2′-acetyl erythromycin **2a** was prepared by a treatment of **1a** with acetic anhydride in the absence of acylation catalysts.[16] No acylation of other hydroxyl groups was detected even in the presence of a large excess of acetic anhydride. This is possible due to the vicinity of NMe_2 group in desosamine residue which substantially increases rates of both introduction and removal of 2′-acyl group.[6] In contrast, acylation of **1a** with an excess of acetic anhydride in the presence of DMAP yielded a complex mixture in which products possessing one to four acetyl groups were detected by ESI-MS. Compound **2a** was then acylated by DCC coupling through non-symmetric malonate method[15,17] using *tert*-butyldiphenylsilyl and benzyl malonates. The reaction of 2′-acetyl erythromycin **2a** with *tert*-butyldiphenylsilyl malonate and DCC was found to provide a mixture of starting material, mono-, and diacylation products. In contrast, acylation of **2a** with benzyl malonate/DCC system proceeded smoothly to give benzyl ester **3b** without diacylation. Reasons for such a different reactivity are not clear since *tert*-butyldiphenylsilyl malonate was found to be less reactive than benzyl malonate in acylation of other sterically hindered alcohols. The structure of **3b** was verified by the ESI MS–MS technique. Fragmentation of MH^+ of **3a** produced MH^+-cladinose-$C(O)CH_2CO_2Bn$ cations. No traces of MH^+-cladinose ions that would indicate the presence of isomers other than 4″-benzylmalonylerythromycin were observed.

We initially planned to remove the 2′-acyl group by methanolysis of ester **3b**. However, there was a considerable decrease in the methanolysis rates of malonyl derivative **3b** in comparison to 2′-acetyl erythromycin **2a**



Scheme 2. Preparation of cladinose tethered derivatives of erythromycin and clarithromycin. Reagents and conditions: (a) $(R^1CO)_2O$, DCM, rt; (b) $R^2OCOCH_2CO_2H$, DCC, rt; (c) MeOH, rt, 24 h, then H_2/Pd/MeOH/acetate buffer; (d) HXR^3, DCC, DCM, rt.